HCoV-229E S protein inhibitors(HCoV-229E S protein inhibitors), SARS-CoV S protein inhibitors(SARS-CoV S protein inhibitors), SARS-CoV-2 S protein inhibitors(Coronavirus spike glycoprotein inhibitors)

+ [1]

Therapeutic Areas

Infectious Diseases

Active Indication

Coronavirus Infections

Inactive Indication-

Originator Organization

Korea University

Active Organization

Korea University

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

100 Clinical Results associated with 6RBD-np

100 Translational Medicine associated with 6RBD-np

100 Patents (Medical) associated with 6RBD-np

Literatures (Medical) associated with 6RBD-np

01 May 2024·Cell Reports

Mosaic RBD nanoparticle elicits immunodominant antibody responses across sarbecoviruses

Article

Author: Dai, Lianpan ; Zheng, Yuxuan ; Gao, George F ; Chai, Yan ; Xu, Kun ; Xu, Senyu ; Luo, Tingrong ; Liu, Chuanyu ; Xie, Yufeng

Nanoparticle vaccines displaying mosaic receptor-binding domains (RBDs) or spike (S) from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or other sarbecoviruses are used in preparedness against potential zoonotic outbreaks. Here, we describe a self-assembling nanoparticle using lumazine synthase (LuS) as the scaffold to display RBDs from different sarbecoviruses. Mosaic nanoparticles induce sarbecovirus cross-neutralizing antibodies comparable to a nanoparticle cocktail. We find mosaic nanoparticles elicit a B cell receptor repertoire using an immunodominant germline gene pair of IGHV14-3:IGKV14-111. Most of the tested IGHV14-3:IGKV14-111 monoclonal antibodies (mAbs) are broadly cross-reactive to clade 1a, 1b, and 3 sarbecoviruses. Using mAb competition and cryo-electron microscopy, we determine that a representative IGHV14-3:IGKV14-111 mAb, M2-7, binds to a conserved epitope on the RBD, largely overlapping with the pan-sarbecovirus mAb S2H97. This suggests mosaic nanoparticles expand B cell recognition of the common epitopes shared by different clades of sarbecoviruses. These results provide immunological insights into the cross-reactive responses elicited by mosaic nanoparticles against sarbecoviruses.

24 Jan 2023·Proceedings of the National Academy of SciencesQ1 · CROSS-FIELD

Mosaic RBD nanoparticles induce intergenus cross-reactive antibodies and protect against SARS-CoV-2 challenge

Q1 · CROSS-FIELD

Article

Author: Lee, Dan Bi ; Chung, Mi Sook ; Jang, Yuyeon ; Radwanska, Magdalena ; Roh, Seokbeom ; Baek, Yun Hee ; Kim, Kyung Hyun ; Magez, Stefan ; Jeon, Hyunbum ; Jun, Hyun Sik ; Song, Min-Suk ; Jeong, Ju Hwan ; Mun, Ji Young ; Kim, Hyojin ; Kim, Eun Jeong ; Lee, Hye-Ra ; Lee, Gyudo ; Han, Su Yeon ; Jang, Ui Soon ; Maeng, Jin Young

Recurrent spillovers of α- and β-coronaviruses (CoV) such as severe acute respiratory syndrome (SARS)-CoV, Middle East respiratory syndrome-CoV, SARS-CoV-2, and possibly human CoV have caused serious morbidity and mortality worldwide. In this study, six receptor-binding domains (RBDs) derived from α- and β-CoV that are considered to have originated from animals and cross-infected humans were linked to a heterotrimeric scaffold, proliferating cell nuclear antigen (PCNA) subunits, PCNA1, PCNA2, and PCNA3. They assemble to create a stable mosaic multivalent nanoparticle, 6RBD-np, displaying a ring-shaped disk with six protruding antigens, like jewels in a crown. Prime-boost immunizations with 6RBD-np in mice induced significantly high Ab titers against RBD antigens derived from α- and β-CoV and increased interferon (IFN-γ) production, with full protection against the SARS-CoV-2 wild type and Delta challenges. The mosaic 6RBD-np has the potential to induce intergenus cross-reactivity and to be developed as a pan-CoV vaccine against future CoV spillovers.

NanoscaleQ2 · MATERIALS SCIENCE

UV-trained and metal-enhanced fluorescence of biliverdin and biliverdin nanoparticles

Q2 · MATERIALS SCIENCE

Article

Author: Mehta, Kritika ; Roslend, Ayman ; Fathi, Parinaz ; Zhang, Kai ; Moitra, Parikshit ; Pan, Dipanjan

UV irradiation and metal chelation can be utilized alone or in combination to tailor the fluorescence behavior of biliverdin-based imaging probes at selected wavelengths.

100 Deals associated with 6RBD-np

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Coronavirus Infections	Preclinical	South Korea	Korea University	24 Jan 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

6RBD-np

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation